TY  - GEN
AU  - Uchino,Junji
AU  - Uchino,Junji
TI  - Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments
SN  - books978-3-0365-0131-4
PY  - 2021///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - non-small cell lung cancer
KW  - previously treated patients
KW  - phase I/II trial
KW  - chemotherapy
KW  - docetaxel
KW  - S-1
KW  - immunotherapy
KW  - rechallenge
KW  - retrospective analysis
KW  - pulmonary pleomorphic carcinoma
KW  - prognostic factor
KW  - glucose transporter 1
KW  - lung cancer
KW  - multiple cancers
KW  - metastasis
KW  - sequencing
KW  - mutation
KW  - genomic diagnosis
KW  - FDG-PET
KW  - immune checkpoint inhibitor
KW  - PD-1
KW  - prognosis
KW  - RAD51B methylation
KW  - PD-L1 expression
KW  - predictive biomarker
KW  - PD-1 blockade
KW  - interstitial lung disease
KW  - pulmonary fibrosis
KW  - radiology and other imaging
KW  - non-small-cell lung cancer
KW  - epidermal growth factor receptor
KW  - tyrosine kinase inhibitors
KW  - TP53 mutations
KW  - responsiveness
KW  - targeted therapy
KW  - network meta-analysis
KW  - stage IIIA-N2
KW  - surgery
KW  - immune checkpoint inhibitors
KW  - biomarker
KW  - nonsmall cell lung cancer
KW  - HIP1R
KW  - PD-L1
KW  - RUNX1
KW  - methylation
KW  - survival
KW  - EGFR-TKI
KW  - T790M
KW  - osimertinib
KW  - immune-related adverse events
KW  - endocrine disorders
KW  - tumor-bearing patients
KW  - PD-1 inhibitors
KW  - PD-L1 inhibitors
KW  - meta-analysis
KW  - nivolumab
KW  - Expanded Access Program
KW  - real-world data
KW  - daily practice
KW  - prognostic factors
KW  - NSCLC
KW  - KRAS
KW  - DNA polymerase beta
KW  - platinum-based first-line
KW  - adjuvant chemotherapy
KW  - β-catenin
KW  - lung neoplasms
KW  - nucleotide-diphosphate kinase
KW  - recurrence
KW  - unresectable
KW  - salvage surgery
KW  - oligometastasis
N1  - Open Access
N2  - Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied
UR  - https://mdpi.com/books/pdfview/book/4666
UR  - https://directory.doabooks.org/handle/20.500.12854/77051
ER  -